Metastasis is one of the most relevant negative prognostic indicators for many types of cancer. We hypothesized that CDK5 activity, which controls neuronal migration during brain neocortical development, also may control metastasis in some cancers. We have found that CDK5, heretofore thought to be active mainly in neuronal lineages, is active in several types of cancer, due to expression of its activator protein p35. Blocking CDK5 activity resulted in inhibition of cancer cell motility and invasion, and, in a prostate cancer model, a 79% decrease in spontaneous metastasis. This indicates that CDK5 activity may be a central control for metastasis, and CDK5 may be a potential therapeutic target to limit metastasis. This application will explore the role of CDK5 in metastasis, and its function in the biology of cancer.
In Specific Aim 1, a genetically engineered animal model for the role of CDK5 in metastasis and tumor biology will be developed. The effect of Cdk5 ablation on tumor growth, differentiation, angiogenesis, immune response, and, especially, metastasis will be investigated. Potential pathways for escape from Cdk5 ablation-mediated inhibition of metastasis will be explored.
In Specific Aim 2, the functions of CDK5 in cancer will be explored, using gene expression analysis of CDK5 inhibition in prostate cancer. Advanced biostatistical analysis methods will be applied to microarray gene expression data, to look for transcription signatures that may predict mechanisms of control of metastasis, as well as novel functions of Cdk5 in tumor biology, and potential sensitization to other therapies. Data analysis methods will include GSEA, Bayesian Decomposition, and other analytical tools, including analytical methods under development in Dr. Ochs's group. Functional biological analyses will be employed to confirm predictions derived from these analyses of transcriptional signatures.
In Specific Aim 3, the mechanism of receptor tyrosine kinase control of p35 expression will be explored. We will confirm that ErbB-family mediated activation of p35 is at the transcriptional level, and then identify the transcription factor(s) that mediate this induction. The effect of the identified transcription factor on p35 expression will be examined, using gene transfer and siRNA. The correlation of expression of the identified transcription factor with p35 expression will be examined in a panel of cell lines. Narrative: In many types of cancer, metastatic spread is closely linked to lethality, and control of metastasis may be an important step in increasing survival. We have identified a cellular enzyme, CDK5, whose activity appears to be required for metastasis in prostate and other cancers. This project seeks to define the role of CDK5, a potential therapeutic target, in control of metastasis and tumor function.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Wissing, Michel D; Dadon, Tikva; Kim, Eunice et al. (2014) Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep 32:419-24
Feldmann, Georg; Mishra, Anjali; Bisht, Savita et al. (2011) Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12:598-609
Feldmann, Georg; Mishra, Anjali; Hong, Seung-Mo et al. (2010) Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 70:4460-9
Strock, Christopher J; Park, Jong-In; Nakakura, Eric K et al. (2006) Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 66:7509-15
Kim, Eun-Joo; Park, Jong-In; Nelkin, Barry D (2005) IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem 280:4913-20
Park, Jong-In; Strock, Christopher J; Ball, Douglas W et al. (2005) Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine 29:125-34
Nakakura, Eric K; Sriuranpong, Virote R; Kunnimalaiyaan, Muthusamy et al. (2005) Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab 90:4350-6
Park, Jong-In; Powers, James F; Tischler, Arthur S et al. (2005) GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Exp Cell Res 303:79-88
Strock, Christopher J; Park, Jong-In; Rosen, Mark et al. (2003) CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63:5559-63
Park, Jong-In; Strock, Christopher J; Ball, Douglas W et al. (2003) The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 23:543-54